Profil
Robert H.
Murdock worked as a Director of Clinical Development at Salix Pharmaceuticals Ltd.
in 2002-2003, Director of Clinical Safety at GSK Plc, Vice President of Clinical Operations at American Bioscience, Inc., and Vice President of Clinical Operations at Abraxis BioScience, Inc. in 2006-2007 and 2007-2011.
He received an undergraduate degree from Wake Forest University and a graduate degree from The University of North Carolina at Charlotte.
Anciens postes connus de Robert H. Murdock
| Sociétés | Poste | Fin |
|---|---|---|
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Corporate Officer/Principal | 30/03/2011 |
Abraxis BioScience, Inc. /Old/
 Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL | Corporate Officer/Principal | 01/11/2007 |
| SALIX PHARMACEUTICALS, LTD. | Corporate Officer/Principal | 01/08/2003 |
| GSK PLC | Corporate Officer/Principal | - |
| American Bioscience, Inc. | Corporate Officer/Principal | - |
Formation de Robert H. Murdock
| Wake Forest University | Undergraduate Degree |
| The University of North Carolina at Charlotte | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GSK PLC | Health Technology |
| Entreprise privées | 4 |
|---|---|
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL | Health Technology |
| American Bioscience, Inc. | Health Technology |
Salix Pharmaceuticals Ltd.
 Salix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Salix Pharmaceuticals Ltd. develops and commercializes prescription drugs and medical devices used in the treatment of gastrointestinal diseases, endocrinology, hepatology, colorectal surgery, and internal medicine. It offers Anusol, Apriso, Colazal, Deflux, Diuril, Fenoglide, MoviPrep, Pepcid, Solesta, and Zegerid. The company was founded by randy W. Hamilton and Lorin K. Johnson in1989 and is headquartered in Bridgewater, NJ. | Health Technology |
